Mental health studies with practical context.

A multicenter, parallel-group, double-blind, randomized, placebo-controlled, increasing-dose study, to evaluate preliminarily the clinical effects, the safety and tolerability of ABIO 08/01, in pat...

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Italy

Sponsor

ABIOGEN PHARMA

A Investigative Extension study of the Safety and Efficacy of Aripiprazole in the Treatment of people with Bipolarity Experiencing a Manic or Mixed Episode

This study has finished and is no longer accepting participants.

Countries

China, Japan, South Korea, + 1 other

Sponsor

Otsuka Pharmaceutical Co., Ltd. (Pharmaceutical company)

A Multicenter, Randomized, Double-blind Trial of Brexpiprazole versus Placebo for the Acute Treatment of Manic Episodes, With or Without Mixed Features, Associated With Bipolarity type I

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Croatia

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)

A Multicenter, Randomized, Double-Blind, Active Controlled, Comparative, Fixed-Dose, Dose Response Study of the Efficacy and Safety of BMS-820836 in Patients with Treatment Resistant Major Depress...

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

United Kingdom, Austria, Italy, + 1 other

Sponsor

Bristol-Myers Squibb International Corporation

A Multicenter, Randomized, Double-blind, Active-Controlled Study of the Efficacy and Safety of Flexibly-Dosed BMS-820836 in Patients with Treatment Resistant Major Depression Revised protocol ...

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Finland, Sweden

Sponsor

Bristol-Myers Squibb International Corporation

A Multicenter, Randomized, Double-Blind, Fixed-Dose, 6-Week Trial of the Efficacy and Safety of Asenapine Compared With Placebo Using Olanzapine as an Active Control in Subjects With an Acute Ex...

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Bulgaria

Sponsor

Schering-Plough Research Institute, a Division of Schering

A Multicenter, Randomized, Double-blind, Placebo- and Active controlled Trial to Evaluate the Efficacy of Brexpiprazole Monotherapy for the Treatment in Adolescents (13-17 years old) With Schizophr...

This study has finished and is no longer accepting participants.

Recruitment status comes from the linked ClinicalTrials.gov record. Both registries list the identifiers for the same study.

Countries

United States

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PREGABALIN IN SUBJECTS WITH GENERALIZED ANXIETY DISORDER (GAD) SWITCHING FROM BENZODIAZEPINE THERAPY Estudio multicéntrico, alea...

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Czechia, Italy, Spain

Sponsor

Pfizer España

A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of iloperidone for 4 weeks in the treatment of patients with acute manic episodes associated wi...

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Bulgaria, Poland

Sponsor

Vanda Pharmaceuticals Inc.

A Parallel Group-comparison study of Aripiprazole in the Treatment of people with Bipolarity Experiencing a Manic or Mixed Episode

This study has finished and is no longer accepting participants.

Countries

China, Japan, South Korea, + 1 other

Sponsor

Otsuka Pharmaceutical Co., Ltd. (Pharmaceutical company)

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate Efficacy and Safety of Prolonged Release (PR) OROS® methylphenidate (54 and 72 mg/day) i...

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

France, United Kingdom, Belgium, + 6 others

Sponsor

Janssen-Cilag International N.V., Turnhoutseweg 30, B-2340 Beerse, Belgium

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Study with Vilazodone in Patients with Major Depressive Disorder

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Bulgaria, Finland, Germany

Sponsor

Forest Research Institute, Inc., a wholly owned subsidiary of Forest Laboratories, Inc.